Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Axonics Modulation Technologies Inc. (AXNX) Misses Q4 EPS by 18c, Revenues Beat
March 5, 2019 4:27 PM ESTAxonics Modulation Technologies Inc. (NASDAQ: AXNX) reported Q4 EPS of ($0.50), $0.18 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $494 thousand versus the consensus estimate of $220 thousand.
In Q4, commercial sales of the miniaturized rechargeable Axonics r-SNM® System totaled $0.5 million.On February 11, filed full-body magnetic resonance imaging (MRI) data with the U.S. Food and Drug Administration (FDA) seeking conditional labeling for the miniaturized rechargeable Axonics r-SNM System.On February 19, disclosed top-line six-month clinical results on the full cohort of patients for the ARTISAN-SNM pivotal clinical study of the... More